Immune Pharmaceuticals raises $11.7m on Nasdaq
Avraham Pharmaceuticals has begun a Phase II clinical trials of its treatment, which combines existing drugs from Teva and Novartis.
Avraham Pharmaceuticals Ltd., which is developing a treatment for Alzheimer's disease, has raised $3 million. Eli Hurvitz's Pontifax Fund, Clal Biotechnology Industries Ltd. (TASE: CBI), Yissum Technology Transfer Company of the Hebrew University of Jerusalem, and the Technion Research and Development Foundation have participated in the financing round. Prof. Marta Weinstock-Rosin of Hebrew University, the inventor of Exelon, made by Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ), also participated in the round.
Avraham Pharmaceuticals announced that it has begun Phase II clinical trials of its treatment, which is a new molecule in which components from two existing drugs are combined: Teva's Azilect used to treat Parkinson's disease, and Novartis's Exelon used to treat Alzheimer's disease.
The drug was developed by Teva for over ten years, but then returned to Yissum and the Technion because of patent considerations and the project was taking such a long time. Since then, the company has been re-established, has raised $9 million, and a few changes in the patent were made making it valid for a longer period of time. Teva has proven in clinical trials that the drug is safe and that it affects the body as expected, ie. causes a rise or fall in the level of chemicals associated with Alzheimer's in the blood. The drug has not, however, reached the trial stage in which its benefit to real patients has been examined. Avraham Pharmaceuticals now has the responsibility to prove this.
In addition to its experiments concerning Alzheimer's disease, Avraham Pharmaceuticals will soon begin clinical trials of a drug that treats mild cognitive impairment, which is thought to precede Alzheimer's disease.
Yissum Technology has announced that its 30% stake in Avraham Pharmaceuticals (after the latest investment) will be transferred to a new holding company that it founded in the biotech field.
Sources inform "Globes" that besides Avraham Pharmaceuticals, the holding company will include six other companies that are currently conducting clinical trials: Tiltan Pharma, VCD, Autocas Bio, Lipicure, Algen Biopharmaceuticals and Novotyr Therapeutics. The holding company is called Integra and it is currently in the midst of a private financing round. Integra will be managed by Dr. Noa Shelach, a former Weizmann Institute Yeda manager, and CBI-Weizmann Institute Campus Bio project manager.
Published by Globes [online], Israel business news - www.globes-online.com - on November 13, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
You comment was recieved and soon will be published.
Load more comments
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.